Breast cancer adjuvant therapy: Time to consider its time-dependent effects

Journal of Clinical Oncology

Volumn 29, Issue 17, 2011, Pages 2301-2304

  Jatoi, Ismail ^a   Anderson, William F ^b   Jeong, Jong Hyeon ^c   Redmond, Carol K ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CHRONOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; TIME FACTORS;

EID: 79959218808     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.3550     Document Type: Note

References (31)

1. Jatoi I, Tsimelzon A, Weiss H, et al: Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89:173-178, 2005 (Pubitemid 40249051)
2. Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database: Incidence-SEER 13 Regs Research Data, November 2009 Submission (1992-2007) Katrinia/Rita Population Adjustment - Linked To County Attributes. Total U.S., 1969-2007 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on November 2009 submission. http://seer.cancer.gov/
3. Akaike H: Information theory and an extension of the maximum likelihood principle, in Petrov BN, Csaki F (eds): 2nd International Symposium on Information Theory. Budapest, Hungary, Akademiai Kiado, 1973, pp 267-281
4. Rosenberg PS: Hazard function estimation using B-splines. Biometrics 51:874-887, 1995
5. Efron B, Tibshirani R: An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability 57. New York, NY, Chapman & Hall, 1993
6. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006 (Pubitemid 44200649)
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
9. Sotiriou C, Piccart MJ: Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nat Rev Cancer 7:545-553, 2007
10. Desmedt C, Piette F, Loi S, et al: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207-3214, 2007 (Pubitemid 46944903)
11. Dinh P, Sotiriou C, Piccart MJ: The evolution of treatment strategies: Aiming at the target. Breast 16:S10-S16, 2007 (suppl 2)
12. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
13. Anderson WF, Jatoi I, Devesa SS: Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: Suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90:127-137, 2005 (Pubitemid 40568896)
14. Anderson WF, Chen BE, Jatoi I, et al: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer after primary diagnosis. Breast Cancer Res Treat 100:121-126, 2006
15. Berry D: Commentary: The hazards of survival comparisons. Oncologist 12:510-511, 2007
16. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
17. Jeong JH, Jung SH, Wieand S: A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med 22:339-352, 2003
18. Demicheli R, Miceli R, Moliterni A, et al: Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 16:1449-1457, 2005 (Pubitemid 41222417)
19. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
20. Hoos A, Eggermont AM, Janetzki S, et al: Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388-1397, 2010
21. Krieger N, Chen JT, Ware JH, et al: Race/ethnicity and breast cancer estrogen receptor status: Impact of class, missing data, and modeling assumptions. Cancer Causes Control 19:1305-1318, 2008
22. Berry DA: The hazards of endpoints. J Natl Cancer Inst 102:1376-1377, 2010
23. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
24. Oakes D, Jeong JH: Frailty models and rank tests. Lifetime Data Anal 4:209-228, 1998 (Pubitemid 128480558)
25. Harrington DP, Fleming TR: A class of rank test procedures for censored survival data. Biometrika 69:553-566, 1982
26. Gore SM, Pocock SJ, Kerr GR: Regression models and non-proportional hazards in the analysis of breast cancer survival. Appl Stat 33:176-195, 1984
27. Therneau TM, Grambsch PM: Modeling SURVIVAL DATA: Extending the Cox Model. New York, NY, Springer, 2000
28. Perperoglou A, Keramolpoullos A, Houwelingen HC: Approaches in modelling long-term survival: An application to breast cancer. Stat Med 26:2666-2685, 2007 (Pubitemid 46831676)
29. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley & Sons, 1980
30. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999 (Pubitemid 29126745)
31. Fisher LD, Lin DY: Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20:145-157, 1999 (Pubitemid 29242575)